Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

5.29
-0.2300-4.17%
Post-market: 5.27-0.0200-0.38%19:58 EDT
Volume:1.94M
Turnover:10.51M
Market Cap:238.04M
PE:-2.44
High:5.72
Open:5.54
Low:5.27
Close:5.52
52wk High:54.97
52wk Low:4.01
Shares:45.00M
Float Shares:16.73M
Volume Ratio:0.84
T/O Rate:11.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1683
EPS(LYR):-1.8835
ROE:-32.34%
ROA:-21.54%
PB:0.90
PE(LYR):-2.81

Loading ...

Sionna Therapeutics upgraded to Sector Perform from Underperform at RBC Capital

TIPRANKS
·
Aug 10

Sionna Therapeutics, Inc. : RBC Raises to Sector Perform from Underperform; Cuts Target Price to $5 from $23

THOMSON REUTERS
·
Aug 10

Tenax, Sionna Shares Sink After Trial Failures

Dow Jones
·
Aug 10

Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53

MT Newswires Live
·
Aug 10

Sionna Therapeutics Shares Down 91% After Co's Experimental Drug Misses Mid-Stage Trial Goal

THOMSON REUTERS
·
Aug 10

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

MT Newswires Live
·
Aug 10

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Amid Rising Oil Prices

MT Newswires Live
·
Aug 10

Sionna Shares Tumble After Cystic-Fibrosis Treatment Unexpectedly Misses Endpoint

Dow Jones
·
Aug 10

Sionna Scraps Genetic Disorder Drug Program After Trial Setback; Shares Tank

Reuters
·
Aug 10

U.S. Stocks on the MOVE-Apple, Barrick Mining, AbCellera Biologics

Reuters
·
Aug 10

Top Premarket Decliners

MT Newswires Live
·
Aug 10

Sionna Falls After Experimental Drug Misses Mid-Stage Trial Goal

Reuters
·
Aug 10

Sionna Therapeutics Says SION-719 Phase 2a Trial Misses Sweat Chloride Endpoint in Cystic Fibrosis

Reuters
·
Aug 10

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Evaluating Sion-719 Trial Confounders to Inform Sion-451 Program Next Steps

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Ends Q2 with $268.30 Mln in Cash; Plans Capital Preservation Actions

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Sion-719 Phase 2a Trial Does not Meet Key Endpoint; Program Discontinued as Add-on

THOMSON REUTERS
·
Aug 10

RBC Capital Remains a Sell on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Aug 08

Sionna Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 08

Sionna Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06